Chemotherapy plus AK112 before surgery for stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial is testing whether an experimental drug called AK112, combined with chemotherapy, can shrink stomach cancer before surgery, making it easier to remove. It is specifically for a type of stomach cancer that contains signet ring cells, and the goal is to see if this approach improves outcomes compared to standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old and have a diagnosis of stomach or gastroesophageal junction cancer that includes signet ring cells (a specific type of cancer cell).
- Your cancer must be locally advanced (grown into nearby tissue but not spread to distant organs) and considered removable with surgery.
- You must not have had any prior treatment for this cancer, such as chemotherapy, radiation, or immunotherapy.
- You must be generally able to care for yourself (do light activity, though you may need to rest).
- You must be willing to use effective contraception during and for a period after treatment, and if you are breastfeeding, you cannot participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a targeted radiation treatment during surgery to the usual combination of immunotherapy and chemotherapy helps people with advanced stomach cancer before they have surgery to remove the tumor. The goal is to see if this extra treatment can improve outcomes.
This trial tests a combination of chemotherapy drugs and an immunotherapy drug given before surgery for stomach cancer in younger patients. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests whether giving immunotherapy (a treatment that helps your immune system fight cancer) along with chemotherapy and radiation before surgery can help shrink tumors in people with stomach cancer at the esophagus-stomach junction. The goal is to see if this approach is safe and effective before the main surgery.
This trial tests a combination of three drugs (Disitamab Vedotin, Toripalimab, and XELOX) given before and after surgery for gastric or gastroesophageal junction cancer. The goal is to see if this treatment helps shrink the tumor and prevent it from coming back.
This trial tests a combination of two targeted drugs, with or without chemotherapy, given before and after surgery for stomach or gastroesophageal junction cancer. It aims to improve the chance of curing the cancer by shrinking it before surgery and controlling any remaining cancer after surgery.
This trial tests a combination chemotherapy plan—paclitaxel (albumin-bound), oxaliplatin, and S-1 given before surgery—to try to shrink stomach cancer and improve the chance of successful tumor removal. It is for people whose cancer is locally advanced or has spread, but might still be resectable (removable) in certain cases.
Hear when a new Gastric or Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.